An FDA advisory panel voted to endorse Grail’s Galleri multicancer blood test, saying the benefits outweigh the risks while acknowledging ongoing questions about effectiveness across cancer types and how results might affect screening behavior. The Molecular and Clinical Genetics panel voted 10–0 on safety and 6–4 on effectiveness. The panel’s discussion focused on the risk balance of false reassurance versus the potential for earlier detection, and reiterated that Galleri should not replace guideline-based diagnostics for breast, cervical, colorectal and lung cancer. Although the vote is not a final FDA decision, it signals that reviewers see sufficient early signals to justify further regulatory consideration—while leaving unresolved the magnitude of clinical utility that will be critical for final approval language.